Pharmacoeconomic review report Adalimumab (Humira)
Adalimumab (Humira) is an anti-℗tumour necrosis factor alpha (TNF alpha), available as a syringe of 40 mg/0.8 mL solution for subcutaneous injection at a unit price of 40.36 per syringe. The current review of adalimumab is for the treatment of adult patients with moderately to severely active ulcer...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2016.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270906719 |
